Table 4.
Cost-effectiveness base-case results
| Diagnostic options | Total | Incremental outcomes (piflufolastat F 18 vs each comparator) | Combined outcomes | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Cost (USD) | LY | QALY | Δ Cost (USD) | Δ LY | Δ QALY | ICER (Δ $/Δ LY) | ICER (Δ $/Δ QALY) | Net monetary benefit (threshold of $150,000) | |
| Piflufolastat F 18 | 172,235 | 6.80 | 5.334 | 627,918 | |||||
| Comparators | |||||||||
| Fluciclovine F 18 | 170,413 | 6.72 | 5.262 | 1822 | 0.0863 | 0.0720 | 21,122 | 25,288 | 618,933 |
| PSMA 11 | 169,810 | 6.76 | 5.300 | 2425 | 0.0434 | 0.0341 | 55,836 | 71,032 | 625,222 |
| SOC imaging (MRI, SPECT, CT equally weighted) | 144,378 | 6.58 | 5.119 | 27,857 | 0.2241 | 0.2157 | 124,330 | 129,151 | 623,421 |
Costs are presented in 2021 United States dollars (USD)
CT computed tomography, ICER incremental cost-effectiveness ratio, LY life-year, MRI magnetic resonance imaging, PSMA prostate-specific membrane antigen, QALY quality-adjusted life-year, SOC standard of care, SPECT single-photon emission computerized tomography